Vaxcyte Inc
Suletud
SektorTervishoid
57.98 3.33
Ülevaade
Aktsiahinna muutus
24h
Min
57.2
Max
58.34
Sissetulek | -74M -321M |
|---|---|
Aktsiakasum | -2.3 |
Töötajad | 507 |
EBITDA | -80M -315M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +98.66% upside |
Järgmine tulemuste avaldamine | 4. aug 2026 |
|---|
Turukapital | -111M 8.3B |
|---|---|
Eelmine avamishind | 54.65 |
Eelmine sulgemishind | 57.98 |
Vaxcyte Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Vaxcyte Inc Prognoos
Hinnasiht
By TipRanks
98.66% tõus
12 kuu keskmine prognoos
Keskmine 116 USD 98.66%
Kõrge 163 USD
Madal 75 USD
Põhineb 6 Wall Streeti analüütiku instrumendi Vaxcyte Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Vaxcyte Inc
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.